NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Esmolol | The risk or severity of adverse effects can be increased when Esmolol is combined with NGX267. |
| Betaxolol | The risk or severity of adverse effects can be increased when Betaxolol is combined with NGX267. |
| Metoprolol | The risk or severity of adverse effects can be increased when Metoprolol is combined with NGX267. |
| Atenolol | The risk or severity of adverse effects can be increased when Atenolol is combined with NGX267. |
| Timolol | The risk or severity of adverse effects can be increased when Timolol is combined with NGX267. |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with NGX267. |
| Propranolol | The risk or severity of adverse effects can be increased when Propranolol is combined with NGX267. |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with NGX267. |
| Bisoprolol | The risk or severity of adverse effects can be increased when Bisoprolol is combined with NGX267. |
| Alprenolol | The risk or severity of adverse effects can be increased when Alprenolol is combined with NGX267. |
| Pindolol | The risk or severity of adverse effects can be increased when Pindolol is combined with NGX267. |
| Carvedilol | The risk or severity of adverse effects can be increased when Carvedilol is combined with NGX267. |
| Propafenone | The risk or severity of adverse effects can be increased when Propafenone is combined with NGX267. |
| Acebutolol | The risk or severity of adverse effects can be increased when Acebutolol is combined with NGX267. |
| Nadolol | The risk or severity of adverse effects can be increased when Nadolol is combined with NGX267. |
| Bevantolol | The risk or severity of adverse effects can be increased when Bevantolol is combined with NGX267. |
| Practolol | The risk or severity of adverse effects can be increased when Practolol is combined with NGX267. |
| Penbutolol | The risk or severity of adverse effects can be increased when Penbutolol is combined with NGX267. |
| Oxprenolol | The risk or severity of adverse effects can be increased when Oxprenolol is combined with NGX267. |
| Dexpropranolol | The risk or severity of adverse effects can be increased when Dexpropranolol is combined with NGX267. |
| Celiprolol | The risk or severity of adverse effects can be increased when Celiprolol is combined with NGX267. |
| Nebivolol | The risk or severity of adverse effects can be increased when Nebivolol is combined with NGX267. |
| Bufuralol | The risk or severity of adverse effects can be increased when Bufuralol is combined with NGX267. |
| Bopindolol | The risk or severity of adverse effects can be increased when Bopindolol is combined with NGX267. |
| Bupranolol | The risk or severity of adverse effects can be increased when Bupranolol is combined with NGX267. |
| Indenolol | The risk or severity of adverse effects can be increased when Indenolol is combined with NGX267. |
| Arotinolol | The risk or severity of adverse effects can be increased when Arotinolol is combined with NGX267. |
| Levobetaxolol | The risk or severity of adverse effects can be increased when Levobetaxolol is combined with NGX267. |
| Talinolol | The risk or severity of adverse effects can be increased when Talinolol is combined with NGX267. |
| Anisodamine | The risk or severity of adverse effects can be increased when Anisodamine is combined with NGX267. |
| Bucindolol | The risk or severity of adverse effects can be increased when Bucindolol is combined with NGX267. |
| Esatenolol | The risk or severity of adverse effects can be increased when Esatenolol is combined with NGX267. |
| Cloranolol | The risk or severity of adverse effects can be increased when Cloranolol is combined with NGX267. |
| Mepindolol | The risk or severity of adverse effects can be increased when Mepindolol is combined with NGX267. |
| Epanolol | The risk or severity of adverse effects can be increased when Epanolol is combined with NGX267. |
| Tertatolol | The risk or severity of adverse effects can be increased when Tertatolol is combined with NGX267. |
| Landiolol | The risk or severity of adverse effects can be increased when Landiolol is combined with NGX267. |
| Cimetropium | NGX267 may decrease the anticholinergic activities of Cimetropium. |
| Pegvisomant | The risk or severity of adverse effects can be increased when Pegvisomant is combined with NGX267. |
| Mefloquine | The risk or severity of adverse effects can be increased when Mefloquine is combined with NGX267. |
| Tacrine | The risk or severity of adverse effects can be increased when Tacrine is combined with NGX267. |
| Sulpiride | The risk or severity of adverse effects can be increased when Sulpiride is combined with NGX267. |
| Profenamine | The risk or severity of adverse effects can be increased when Profenamine is combined with NGX267. |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with NGX267. |
| Gallamine triethiodide | The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with NGX267. |
| Triflupromazine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with NGX267. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with NGX267. |
| Cinchocaine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with NGX267. |
| Pyridostigmine | The risk or severity of adverse effects can be increased when Pyridostigmine is combined with NGX267. |
| Nizatidine | The risk or severity of adverse effects can be increased when Nizatidine is combined with NGX267. |
| Galantamine | The risk or severity of adverse effects can be increased when Galantamine is combined with NGX267. |
| Isoflurophate | The risk or severity of adverse effects can be increased when Isoflurophate is combined with NGX267. |
| Diethylcarbamazine | The risk or severity of adverse effects can be increased when Diethylcarbamazine is combined with NGX267. |
| Procaine | The risk or severity of adverse effects can be increased when Procaine is combined with NGX267. |
| Minaprine | The risk or severity of adverse effects can be increased when Minaprine is combined with NGX267. |
| Terbutaline | The risk or severity of adverse effects can be increased when Terbutaline is combined with NGX267. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with NGX267. |
| Hexafluronium | The risk or severity of adverse effects can be increased when Hexafluronium is combined with NGX267. |
| Demecarium | The risk or severity of adverse effects can be increased when Demecarium is combined with NGX267. |
| Physostigmine | The risk or severity of adverse effects can be increased when Physostigmine is combined with NGX267. |
| Rivastigmine | The risk or severity of adverse effects can be increased when Rivastigmine is combined with NGX267. |
| Edrophonium | The risk or severity of adverse effects can be increased when Edrophonium is combined with NGX267. |
| Procainamide | The risk or severity of adverse effects can be increased when Procainamide is combined with NGX267. |
| Memantine | The risk or severity of adverse effects can be increased when Memantine is combined with NGX267. |
| Ambenonium | The risk or severity of adverse effects can be increased when Ambenonium is combined with NGX267. |
| Tubocurarine | The risk or severity of adverse effects can be increased when Tubocurarine is combined with NGX267. |
| Ketamine | The risk or severity of adverse effects can be increased when Ketamine is combined with NGX267. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with NGX267. |
| Decamethonium | The risk or severity of adverse effects can be increased when Decamethonium is combined with NGX267. |
| Pancuronium | The risk or severity of adverse effects can be increased when Pancuronium is combined with NGX267. |
| Pipecuronium | The risk or severity of adverse effects can be increased when Pipecuronium is combined with NGX267. |
| Ginkgo biloba | The risk or severity of adverse effects can be increased when Ginkgo biloba is combined with NGX267. |
| Neostigmine | The risk or severity of adverse effects can be increased when Neostigmine is combined with NGX267. |
| Bambuterol | The risk or severity of adverse effects can be increased when Bambuterol is combined with NGX267. |
| 1,10-Phenanthroline | The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with NGX267. |
| Thiotepa | The risk or severity of adverse effects can be increased when Thiotepa is combined with NGX267. |
| Huperzine A | The risk or severity of adverse effects can be increased when Huperzine A is combined with NGX267. |
| Phenserine | The risk or severity of adverse effects can be increased when Phenserine is combined with NGX267. |
| Regramostim | The risk or severity of adverse effects can be increased when Regramostim is combined with NGX267. |
| Aprotinin | The risk or severity of adverse effects can be increased when Aprotinin is combined with NGX267. |
| Betaine | The risk or severity of adverse effects can be increased when Betaine is combined with NGX267. |
| Capsaicin | The risk or severity of adverse effects can be increased when Capsaicin is combined with NGX267. |
| Coumaphos | The risk or severity of adverse effects can be increased when Coumaphos is combined with NGX267. |
| Dichlorvos | The risk or severity of adverse effects can be increased when Dichlorvos is combined with NGX267. |
| Fenthion | The risk or severity of adverse effects can be increased when Fenthion is combined with NGX267. |
| Metrifonate | The risk or severity of adverse effects can be increased when Metrifonate is combined with NGX267. |
| Acotiamide | The risk or severity of adverse effects can be increased when Acotiamide is combined with NGX267. |
| Methanesulfonyl Fluoride | The risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with NGX267. |
| Paraoxon | The risk or severity of adverse effects can be increased when Paraoxon is combined with NGX267. |
| Tyrothricin | The risk or severity of adverse effects can be increased when Tyrothricin is combined with NGX267. |
| Ipidacrine | The risk or severity of adverse effects can be increased when Ipidacrine is combined with NGX267. |
| Distigmine | The risk or severity of adverse effects can be increased when Distigmine is combined with NGX267. |
| Tretamine | The risk or severity of adverse effects can be increased when Tretamine is combined with NGX267. |
| Posiphen | The risk or severity of adverse effects can be increased when Posiphen is combined with NGX267. |
| Methylphosphinic Acid | The risk or severity of adverse effects can be increased when Methylphosphinic Acid is combined with NGX267. |
| Capreomycin | The therapeutic efficacy of NGX267 can be decreased when used in combination with Capreomycin. |
| Framycetin | The therapeutic efficacy of NGX267 can be decreased when used in combination with Framycetin. |
| Amikacin | The therapeutic efficacy of NGX267 can be decreased when used in combination with Amikacin. |
| Tobramycin | The therapeutic efficacy of NGX267 can be decreased when used in combination with Tobramycin. |
| Gentamicin | The therapeutic efficacy of NGX267 can be decreased when used in combination with Gentamicin. |